27 results
Page of 3
  • AMPLATZER™ Amulet™ Left Atrial Appendage Occluder Randomized Controlled Trial

    A study designed to evaluate the safety and effectiveness of the AMPLATZER Amulet Left Atrial Appendage Occluder.

    Trial is open for enrollment

    View All Details
    • Principal Investigator:
      Dobesh, David M.D.

    For inquiries, call (973) 736-6333
    • Cooperman Barnabas Medical Center
  • Assessing the Normal Microbiome and Virome of the Lung: A Pilot Study

    Trial is open for enrollment.

    View All Details
    • Principal Investigator:
      Subroto Paul M.D.

    For inquiries, call (973) 322-2224
    • Cooperman Barnabas Medical Center
  • Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation (ASAP-TOO)

    Trial is open for enrollment.

    View All Details
    • Principal Investigator:
      Dobesh, David M.D.

    For inquiries, call (973) 736-6333
    • Cooperman Barnabas Medical Center
  • BiSpectral Index (BIS) Monitoring and Sedation Practices in Critically Ill Mechanically Ventilated Patients: A Single Center, Prospective, Randomized Control Trial

    Trial is open for enrollment

    View All Details
    • Principal Investigator:
      Nirav Mistry M.D.

    For inquiries, call (973) 322-2224
    • Cooperman Barnabas Medical Center
  • Enterprise Vascular Remodeling Devices (VRD)

    Trial is open for enrollment.

    View All Details
    • Principal Investigator:
      Ugo Paolucci MD

    For inquiries, call (201) 342-2550
    • Cooperman Barnabas Medical Center
  • ESTEEM - NCT02047097

    This Phase IV study follows patients who are newly initiating dimethyl fumarate (Tecfidera) and monitors clinical effectiveness and the incidence of adverse events in routine clinical care.

    Type: Observational

    Principal Investigator: Andrew Sylvester, MD

    Website: ClinicalTrials.gov Identifier: NCT02047097

    This study is active, but closed to enrollment.

    For inquiries, call (973) 322-7073

    • Cooperman Barnabas Medical Center
    • Barnabas Health Ambulatory Care Center
  • ESTEEM KETONE SUB-STUDY

    An additional sub-study (Ketone Sub- study) to ESTEEM is being offered to approximately 130 patients who are currently enrolled in ESTEEM at ~25 sites in the US in order to assess urine and serum ketones in DMF-treated patients. After enrollment in the sub-study, serum and urine will be collected at each routine visit to measure the serum and urine ketone levels.

    Type: Observational

    Principal Investigator: Andrew Sylvester, MD

    Website: ClinicalTrials.gov Identifier: NCT02047097

    This study is active, and open to enrollment for current study subjects.

    For inquiries, call (973) 322-7073
    • Cooperman Barnabas Medical Center
    • Barnabas Health Ambulatory Care Center
  • FLUENT - NCT03257358

    This Phase IV study aims to characterize how certain immune biomarkers change for MS patients while they are receiving fingolimod (Gilenya) 0.5 mg/day.

    Type: Observational

    Principal Investigator: Andrew Sylvester, MD

    Website: ClinicalTrials.gov Identifier: NCT03257358

    This study is active, but closed to enrollment.

    For inquiries, call (973) 322-7073

    • Cooperman Barnabas Medical Center
    • Barnabas Health Ambulatory Care Center
  • Incidence and Risk Factors Associated with Acute Respiratory Failure in Patients after Renal Transplant

    Trial is open for enrollment.

    View All Details
    • Principal Investigator:
      Nirav Mistry M.D.

    For inquiries, call (973) 322-2224
    • Cooperman Barnabas Medical Center
  • Incidence of Thrombotic Complications in Patients with COVID-19 Admitted to Saint Barnabas Medical Center

    Trial is open for enrollment.

    View All Details
    • Principal Investigator:
      Nirav Mistry M.D.

    For inquiries, call (973) 322-2224
    • Cooperman Barnabas Medical Center
  • IV Methylprednisolone for Progressive MS

    This study aims to investigate the effectiveness of IV Methylprednisolone (IV MP) at 1g /day for 5 days v. sub-therapeutic doses of IV MP for 5 days in RMS, RRMS, and SPMS DMT-treated MS patients who are experiencing functional decline in the absence of relapses (progressive MS).

    Type: Drug Trial

    Principal Investigator: Andrew Sylvester, MD

    This study is open to enrollment.

    For inquiries, call (973) 322-7073

    • Cooperman Barnabas Medical Center
    • Barnabas Health Ambulatory Care Center
  • OCT Study

    Evaluation of Immunomodulator Effects on Retinal Nerve Fiber Layer and Macular Volumes in People with Multiple Sclerosis using Ocular Coherence Tomography

    Type: Retrospective Chart review

    Principal Investigator: Matthew Tremblay, MD, PhD

    Website: IRB Study 20-36

    This study is a retrospective data review.

    For inquiries, call (973) 322-7073
    • Cooperman Barnabas Medical Center
    • Barnabas Health Ambulatory Care Center
Page of 3